5′-Deoxy-5-fluorocytidine (CAS 66335-38-4)
QUICK LINKS
5′-Deoxy-5-fluorocytidine (5prime-dFdC) is a metabolite of the DNA synthesis inhibitor capecitabine (sc-205618). 5′-Deoxy-5-fluorocytidine is an inhibitor of the enzyme ribonucleotide reductase (RNR), which is responsible for the conversion of ribonucleotides to deoxyribonucleotides. Gene expression studies have employed this compound to investigate how gene expression is regulated during transcription. Furthermore, 5′-Deoxy-5-fluorocytidine has found utility in nucleic acid synthesis for creating modified nucleic acids, including oligonucleotides and siRNAs. Additionally, it has been instrumental in biochemistry research, enabling the examination of proteins and other biomolecules′ structure and function. 5′-Deoxy-5-fluorocytidine may act to have anti-inflammatory effects, inhibit the growth of cancer cells, induce apoptosis in cancer cells, and modulate the expression of genes involved in cell cycle regulation and apoptosis.
5′-Deoxy-5-fluorocytidine (CAS 66335-38-4) References
- Rational design of new tumoractivated cytotoxic agents. | Verweij, J. 1999. Oncology. 57 Suppl 1: 9-15. PMID: 10436411
- Clinical pharmacokinetics of capecitabine. | Reigner, B., et al. 2001. Clin Pharmacokinet. 40: 85-104. PMID: 11286326
- Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation. | Tabata, T., et al. 2004. Drug Metab Dispos. 32: 762-7. PMID: 15205393
- Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver. | Tabata, T., et al. 2004. Drug Metab Dispos. 32: 1103-10. PMID: 15269188
- Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. | Quinney, SK., et al. 2005. J Pharmacol Exp Ther. 313: 1011-6. PMID: 15687373
- A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. | Vainchtein, LD., et al. 2010. Biomed Chromatogr. 24: 374-86. PMID: 19650151
- Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens. | Farkouh, A., et al. 2010. Int J Clin Pharmacol Ther. 48: 487-8. PMID: 20557855
- Synthesis and biological activity evaluation of cytidine-5'-deoxy-5-fluoro-N-[(alkoxy/aryloxy)] carbonyl-cyclic 2',3'-carbonates. | Jhansi Rani, V., et al. 2012. Eur J Med Chem. 54: 690-6. PMID: 22796042
- Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. | Kobuchi, S., et al. 2018. Eur J Pharm Sci. 112: 152-158. PMID: 29175408
- Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. | Di Desidero, T., et al. 2018. Invest New Drugs. 36: 709-714. PMID: 29488048
- Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. | Sekido, M., et al. 2019. Cancer Chemother Pharmacol. 83: 1127-1135. PMID: 30972456
- NIR-responsive ROS generating core and ROS-triggered 5'-Deoxy-5-fluorocytidine releasing shell structured water-swelling microgel for locoregional combination cancer therapy. | Lee, J., et al. 2019. J Control Release. 305: 120-129. PMID: 31096018
- Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance. | Inaishi, T., et al. 2020. In Vivo. 34: 3539-3544. PMID: 33144465
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
5′-Deoxy-5-fluorocytidine, 10 mg | sc-221055 | 10 mg | $102.00 |